Pharnext's Pivotal Phase 3 Trial PLEO-CMT To Be Featured At The 22nd Edition Of The Francophone Peripheral Nerve Society Conference
Pharnext SA (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, recently announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).
Details of the presentation are as follows:
Date | Time | Session |
Friday January 26, 2018 | From 3:03 to 3:15pm CET |
Selected Oral Communications Session
|
For more information, visit www.journeessfnp.fr/programme.
Source: Pharnext
This website uses cookies to ensure you get the best experience on our website. Learn more